2028年までの経皮的中枢神経系（CNS）治療薬市場

当レポートは、経皮的中枢神経系（CNS）治療薬市場について調査し、市場の概要とともに、技術動向、需要促進要因、セグメント別薬剤動向、および市場に参入する企業のプロファイルなどをまとめています。

目次

• エグゼクティブサマリー
• 2028年までの経皮的中枢神経系治療薬
• 市場機会
• 経皮ドラッグデリバリーのダイナミクス
• 需要促進要因
• パッチ製造のダイナミクス
• 剥離ライナー
• バッキングフィルム
• 半透膜
• 接着剤
• 経皮的中枢神経系治療薬の市場
• ADHD
• デイトラナ
• メチルフェニデート（Daytrana - Noven）
• アルツハイマー病
• リバスチグミン（Exelon - Novartis）
• アリセプト経皮吸収剤- 最近の活動
• エクセロン
• 鬱病
• 抗鬱薬
• セレギリン（EMSAM - Mylan）
• 吐き気
• アルカロイド
• スコポラミン（Transderm Scop）GlaxoSmithKline Consumer Health
• グラニセトロン（Sancuso - ProStrakan）
• パーキンソン病
• レボドパ
• ロティゴチン（Neupro - Schwarz/UCB)）
• 統合失調症
• アセナピン（Secuado - Noven）
• 経皮的中枢神経系医薬品の分析と市場評価
• FDA承認の経皮的中枢神経系処方製品
• 中枢神経系興奮剤
• AChE阻害剤
• 非定型抗精神病薬
• アルカロイド
• ドーパミンアゴニスト
• 5-HT3受容体拮抗薬
• MAO阻害剤
• 戦略的要素とブランディングの問題
• ドーパミンアゴニスト
• 企業プロファイル

“Transdermal CNS Therapeutics to 2028: Products, Therapeutics, Markets and Forecasts” is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the drug delivery sector. The study is designed to provide drug company decision makers, drug delivery developers, patch designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for Transdermal patches Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Converging Factors Driving Growth in Transdermal Delivery

Transdermal CNS drug patches offer the advantages of ease of use, painlessness, disposability, control of drug delivery and avoidance of first-pass metabolism by the liver. Advances in synthetic materials and patch design have led to patches that are more esthetically acceptable and that are capable of delivering sustained dosing of active compounds for several days in a smaller package. Growth in demand for drug patches is being driven by several factors - factors with strong demographic and population trend underpinnings. Further improvements to transdermal transport and the introduction of new patch designs will keep this segment expanding through 2028.

What You Will Learn:

• Analyzes and evaluates current transdermal CNS therapeutics markets and products and assesses the market potential for existing and probable future products

• Analyzes patch designs, technologies and patch development issues

• Profiles patch manufacturers and third-party transdermal supply chain companies

• Provides detailed assessments of more than a dozen products in more than a dozen product categories

• Provides market data and forecasts to 2028

• Profiles transdermal drug patch product providers, their product development activity, and strategies

• Evaluates the impact of economic, technology, and regulatory factors

Table of Contents

• Executive Summary
• Transdermal CNS Therapeutics to 2028
• The Market Opportunity
• Transdermal Drug Delivery Dynamics
• Demand Drivers
• Patch Manufacturing Dynamics
• Release Liners
• Backing Films
• Semi-permeable Membranes
• Adhesives
• Markets for Transdermal CNS Therapeutics
• ADHD
• Daytrana
• Methylphenidate (Daytrana - Noven)
• Alzheimer's Disease
• Rivastigmine (Exelon - Novartis)
• Aricept Transdermal - Recent Activity
• Exelon
• Depression
• Antidepressants
• Selegiline (EMSAM - Mylan)
• Nausea
• Alkaloids
• Scopolamine (Transderm Scop) GlaxoSmithKline Consumer Health
• Granisetron (Sancuso - ProStrakan)
• Parkinson's Disease
• Levodopa
• Rotigotine (Neupro - Schwarz/UCB))
• Schizophrenia
• Asenapine (Secuado - Noven)
• Transdermal CNS Drug Product Analysis and Market Assessments
• FDA Approved Transdermal CNS Prescription Products
• CNS Stimulants
• AChE Inhibitors
• Atypical Antipsychotics
• Alkaloids
• Dopamine Agonists
• 5-HT3 Receptor Antagonists
• MAO Inhibitors
• Strategic Factors and Branding Issues
• Dopamine Agonists
• Company Profiles